[go: up one dir, main page]

UA102667C2 - Людське нейтралізуюче антитіло проти в7rp1 - Google Patents

Людське нейтралізуюче антитіло проти в7rp1

Info

Publication number
UA102667C2
UA102667C2 UAA200801269A UAA200801269A UA102667C2 UA 102667 C2 UA102667 C2 UA 102667C2 UA A200801269 A UAA200801269 A UA A200801269A UA A200801269 A UAA200801269 A UA A200801269A UA 102667 C2 UA102667 C2 UA 102667C2
Authority
UA
Ukraine
Prior art keywords
b7rp1
antibodies
neutralizing anti
human neutralizing
b7rp1 antibody
Prior art date
Application number
UAA200801269A
Other languages
English (en)
Russian (ru)
Inventor
Джеральд Сію
Уеньян Шен
Стівен Кійосі Йосінага
Хайчунь Хуань
Original Assignee
Емджен Інк.
Медарекс, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Емджен Інк., Медарекс, Інк. filed Critical Емджен Інк.
Publication of UA102667C2 publication Critical patent/UA102667C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Винахід належить до антитіла, що взаємодіє із людським В7-спорідненим білком-1 (B7RP1) і, завдяки цьому, нейтралізує його функціонування, а також до фармацевтичних композицій для лікування імунних розладів шляхом введення фармацевтично ефективної кількості антитіл проти B7RP1. Пропонуються також способи виявлення кількості B7RP1 у зразку із застосуванням антитіл проти B7RP1.
UAA200801269A 2005-07-18 2006-07-18 Людське нейтралізуюче антитіло проти в7rp1 UA102667C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70026505P 2005-07-18 2005-07-18
PCT/US2006/027862 WO2007011941A2 (en) 2005-07-18 2006-07-18 Human anti-b7rp1 neutralizing antibodies

Publications (1)

Publication Number Publication Date
UA102667C2 true UA102667C2 (uk) 2013-08-12

Family

ID=37562100

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200801269A UA102667C2 (uk) 2005-07-18 2006-07-18 Людське нейтралізуюче антитіло проти в7rp1

Country Status (25)

Country Link
US (4) US7868140B2 (uk)
EP (7) EP2397498A3 (uk)
JP (1) JP5142998B2 (uk)
KR (4) KR101024758B1 (uk)
CN (1) CN101321783B (uk)
AU (1) AU2006270009A1 (uk)
BR (1) BRPI0614040B8 (uk)
CA (2) CA2854576A1 (uk)
CR (1) CR9745A (uk)
DK (1) DK1915398T3 (uk)
EA (1) EA021669B1 (uk)
ES (1) ES2572177T3 (uk)
HR (1) HRP20160875T1 (uk)
HU (1) HUE028830T2 (uk)
IL (6) IL188642A (uk)
MX (1) MX2008000734A (uk)
NO (1) NO345593B1 (uk)
NZ (2) NZ604090A (uk)
PL (1) PL1915398T3 (uk)
RS (1) RS54984B1 (uk)
SG (2) SG164369A1 (uk)
SI (1) SI1915398T1 (uk)
UA (1) UA102667C2 (uk)
WO (1) WO2007011941A2 (uk)
ZA (1) ZA200801137B (uk)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2362126C (en) * 1999-02-03 2017-01-17 Amgen Inc. B7rp-1 polypeptides
US7708993B2 (en) 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
CA2854576A1 (en) * 2005-07-18 2007-01-25 Haichun Huang Human anti-b7rp1 neutralizing antibodies
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
MX2010002249A (es) * 2007-08-31 2010-03-17 Amgen Inc Formulacion de proteina de estado solido.
CA2701032C (en) 2007-09-27 2021-01-26 Amgen Inc. Pharmaceutical formulations
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
WO2010064090A1 (en) * 2008-12-02 2010-06-10 Pierre Fabre Medicament Process for the modulation of the antagonistic activity of a monoclonal antibody
AR074438A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US8722046B2 (en) * 2009-04-08 2014-05-13 The United States Of America As Represented By The Secretary Of The Army Human monoclonal antibodies protective against bubonic plague
AU2010310457B2 (en) 2009-10-23 2015-07-02 Amgen Inc. Vial adapter and system
KR102513760B1 (ko) 2010-06-07 2023-03-27 암젠 인크 약물 전달 장치
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
EP2621950A4 (en) 2010-09-27 2015-09-02 Janssen Biotech Inc ANTIBODIES FOR BINDING HUMAN COLLAGEN II
EP2691065B1 (en) 2011-03-31 2017-03-01 Amgen Inc. Vial adapter and system
CA2833748C (en) 2011-04-20 2019-07-16 Amgen Inc. Autoinjector apparatus
EP3335747B1 (en) 2011-10-14 2021-04-07 Amgen Inc. Injector and method of assembly
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP3072548B1 (en) 2012-11-21 2019-03-06 Amgen, Inc Drug delivery device
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) * 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
CN111617347B (zh) 2013-03-15 2023-09-29 安进公司 身体轮廓可调适的自动注射器装置
JP6336564B2 (ja) 2013-03-15 2018-06-06 アムゲン・インコーポレーテッド 薬物カセット、自動注入器、および自動注入器システム
US10492990B2 (en) 2013-03-15 2019-12-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
EP2976117B1 (en) 2013-03-22 2020-12-30 Amgen Inc. Injector and method of assembly
KR102320189B1 (ko) 2013-04-23 2021-11-03 엘라스모겐 리미티드 특이적 결합 분자의 합성 라이브러리
ES2774976T3 (es) 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
SG11201602876WA (en) 2013-10-24 2016-05-30 Amgen Inc Injector and method of assembly
WO2015061389A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Drug delivery system with temperature-sensitive control
AU2015204674B2 (en) * 2014-01-10 2020-09-03 Anaptysbio, Inc. Antibodies directed against interleukin-33 (IL-33)
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
HRP20192097T1 (hr) 2014-03-31 2020-04-03 Universitetet I Tromsø - Norges Arktiske Universitet Protutijela protiv hpa-1a
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
SG10201811702TA (en) 2014-05-07 2019-01-30 Amgen Inc Autoinjector with shock reducing elements
EP3143404B1 (en) 2014-05-16 2018-08-29 Amgen Inc. Assay for detecting th1 and th2 cell populations
MX387194B (es) 2014-06-03 2025-03-18 Amgen Inc Sistemas y metodos para procesar de manera remota datos recolectados por un dispositivo de suministro de farmaco.
EP3943135B1 (en) 2014-10-14 2025-09-24 Amgen Inc. Drug injection device with visual and audible indicators
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
EA037749B1 (ru) 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b
EP3689394A1 (en) 2014-12-19 2020-08-05 Amgen Inc. Drug delivery device with live button or user interface field
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
ES2748750T3 (es) 2015-02-17 2020-03-17 Amgen Inc Dispositivo de administración de fármacos con sujeción asistida por vacío y/o realimentación
US11806509B2 (en) 2015-02-27 2023-11-07 Amgen Inc. Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
ITUB20151014A1 (it) * 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
US11351308B2 (en) 2015-12-09 2022-06-07 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
EP3429663B1 (en) 2016-03-15 2020-07-15 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
KR102824067B1 (ko) 2016-04-15 2025-06-23 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
JP7309363B2 (ja) 2016-05-13 2023-07-18 アムジエン・インコーポレーテツド バイアル・スリーブ組立体
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342B1 (en) 2016-07-01 2025-03-12 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
CA3036997A1 (en) * 2016-09-19 2018-03-22 Oncoimmune, Inc. Cytotoxic t-lymphocyte-associated antigen-4(ctla-4)-fc fusion proteins and use thereof for treating adverse events associated with cancer immunotherapy
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
MX2019008432A (es) 2017-01-17 2019-11-18 Amgen Inc Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
MX2019009755A (es) 2017-02-17 2019-10-07 Amgen Inc Mecanismo de insercion para dispositivo de suministro de farmacos.
US11752258B2 (en) 2017-02-17 2023-09-12 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
WO2018165143A1 (en) 2017-03-06 2018-09-13 Amgen Inc. Drug delivery device with activation prevention feature
WO2018164829A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
IL268386B2 (en) 2017-03-09 2023-11-01 Amgen Inc Insertion mechanism for a drug delivery device
CN110418846A (zh) 2017-03-14 2019-11-05 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型的控制
PL3600491T3 (pl) 2017-03-28 2024-03-04 Amgen Inc. Układ i sposób montażu trzonu tłoka i strzykawki
EP3634546A1 (en) 2017-06-08 2020-04-15 Amgen Inc. Torque driven drug delivery device
WO2018226515A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
WO2018236619A1 (en) 2017-06-22 2018-12-27 Amgen Inc. Device activation impact/shock reduction
JP7475860B2 (ja) 2017-06-23 2024-04-30 アムジエン・インコーポレーテツド スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス
EP3651832B1 (en) 2017-07-14 2023-12-13 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
US11672733B2 (en) 2017-07-21 2023-06-13 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
JP7242562B2 (ja) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
US12318593B2 (en) 2017-08-09 2025-06-03 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
US11759565B2 (en) 2017-10-04 2023-09-19 Amgen Inc. Flow adapter for drug delivery device
EP3691716B1 (en) 2017-10-06 2023-11-29 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
IL273323B2 (en) 2017-10-09 2024-10-01 Amgen Inc Drug delivery device with drive assembly and related assembly method
US11826480B2 (en) 2017-11-03 2023-11-28 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
MA50553A (fr) 2017-11-06 2020-09-16 Amgen Inc Dispositif d'administration de médicament avec détection de positionnement et de débit
SG11202002966QA (en) 2017-11-10 2020-05-28 Amgen Inc Plungers for drug delivery devices
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
JP7747438B2 (ja) 2017-11-16 2025-10-01 アムジエン・インコーポレーテツド 失速及び終点検出を有するオートインジェクタ
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
SG11202009216YA (en) 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
WO2019199476A1 (en) 2018-04-12 2019-10-17 Amgen Inc. Methods for making stable protein compositions
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
EP3826701A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
MX2021000749A (es) 2018-07-24 2021-03-29 Amgen Inc Dispositivos de suministro para administrar farmacos.
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020028009A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
JP2022500095A (ja) 2018-09-24 2022-01-04 アムジエン・インコーポレーテツド インターベンション投薬システム及び方法
IL281469B2 (en) 2018-09-28 2024-08-01 Amgen Inc Muscle wire escapement activation assembly for a drug delivery device
EP3860685A1 (en) 2018-10-02 2021-08-11 Amgen Inc. Injection systems for drug delivery with internal force transmission
US12151089B2 (en) 2018-10-05 2024-11-26 Amgen Inc. Drug delivery device having dose indicator
MA53912A (fr) 2018-10-15 2022-01-19 Amgen Inc Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
SG11202101824VA (en) 2018-10-15 2021-03-30 Amgen Inc Platform assembly process for drug delivery device
EP3873566B1 (en) 2018-11-01 2024-11-27 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
AU2019370159B2 (en) 2018-11-01 2025-05-29 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
US20220160972A1 (en) 2019-04-24 2022-05-26 Amgen Inc. Syringe sterilization verification assemblies and methods
JP7608439B2 (ja) 2019-08-23 2025-01-06 アムジエン・インコーポレーテツド 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
UA129038C2 (uk) 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CN115925900B (zh) * 2020-08-19 2024-06-25 重庆医科大学 新型冠状病毒rbd特异性单克隆抗体和应用
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
US20240208680A1 (en) 2021-05-21 2024-06-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
TW202317614A (zh) 2021-06-07 2023-05-01 美商安進公司 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
JP2024537100A (ja) 2021-10-05 2024-10-10 アムジエン・インコーポレーテツド Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025226754A1 (en) 2024-04-23 2025-10-30 Amgen Inc. Method for predicting osmolality of protein solutions

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
WO1992022646A1 (en) 1991-06-14 1992-12-23 Dnx Corp. Production of human hemoglobin in transgenic pigs
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2362126C (en) * 1999-02-03 2017-01-17 Amgen Inc. B7rp-1 polypeptides
US7435796B1 (en) * 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
AU3921600A (en) 1999-03-25 2000-10-09 Abbott Gmbh & Co. Kg Human antibodies that bind human il-12 and methods for producing
HK1049014A1 (zh) 1999-07-29 2003-04-25 Medarex, Inc. 抗her2/neu的人类单克隆抗体
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
ATE366814T1 (de) * 1999-09-21 2007-08-15 Genetics Inst Llc Gl50 moleküle, sowie verwendungen derselben
GB0016633D0 (en) 2000-07-07 2000-08-23 Bp Exploration Operating Process
AU2002217969B2 (en) * 2000-11-28 2007-12-20 Amgen Canada Inc. Polypeptides involved in immune response
WO2004043989A2 (en) 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
CA2523716C (en) 2003-05-31 2014-11-25 Micromet Ag Human anti-human cd3 binding molecules
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
WO2006003999A1 (ja) * 2004-07-05 2006-01-12 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト抗ヒトb7rp-1抗体およびその抗体フラグメント
CA2854576A1 (en) * 2005-07-18 2007-01-25 Haichun Huang Human anti-b7rp1 neutralizing antibodies
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
EP1915398B1 (en) 2016-04-20
WO2007011941A3 (en) 2007-05-03
US20130171695A1 (en) 2013-07-04
NZ625807A (en) 2015-11-27
BRPI0614040A2 (pt) 2011-03-09
SI1915398T1 (sl) 2016-07-29
KR20140097582A (ko) 2014-08-06
NO345593B1 (no) 2021-05-03
IL188642A (en) 2015-01-29
HRP20160875T1 (hr) 2016-09-23
AU2006270009A1 (en) 2007-01-25
EA200800355A1 (ru) 2008-08-29
KR101263079B1 (ko) 2013-05-09
SG164369A1 (en) 2010-09-29
CA2614972C (en) 2014-08-19
EP2388277A2 (en) 2011-11-23
US10072090B2 (en) 2018-09-11
EP2388277A3 (en) 2013-03-20
RS54984B1 (sr) 2016-11-30
BRPI0614040B8 (pt) 2021-05-25
MX2008000734A (es) 2008-03-19
HUE028830T2 (en) 2017-01-30
WO2007011941A2 (en) 2007-01-25
CR9745A (es) 2008-07-22
KR101024758B1 (ko) 2011-03-24
JP2009501549A (ja) 2009-01-22
EP1915398A2 (en) 2008-04-30
EP2397496A3 (en) 2013-05-29
NZ604090A (en) 2014-07-25
WO2007011941A9 (en) 2008-02-21
US20080166352A1 (en) 2008-07-10
EP2388276A2 (en) 2011-11-23
IL218892A0 (en) 2012-05-31
CA2854576A1 (en) 2007-01-25
US8981071B2 (en) 2015-03-17
IL188642A0 (en) 2008-04-13
EP2397499A2 (en) 2011-12-21
US7868140B2 (en) 2011-01-11
EP2397497A3 (en) 2013-11-27
CN101321783A (zh) 2008-12-10
EP2388276A3 (en) 2013-11-27
HK1120049A1 (zh) 2009-03-20
EP2397498A2 (en) 2011-12-21
CA2614972A1 (en) 2007-01-25
ZA200801137B (en) 2010-05-26
PL1915398T3 (pl) 2016-10-31
US9266945B2 (en) 2016-02-23
US20110104757A1 (en) 2011-05-05
JP5142998B2 (ja) 2013-02-13
IL218890A0 (en) 2012-05-31
DK1915398T3 (en) 2016-07-04
KR20080049014A (ko) 2008-06-03
IL218889A0 (en) 2012-05-31
IL218888A0 (en) 2012-05-31
EP2397498A3 (en) 2013-11-27
CN101321783B (zh) 2015-08-26
IL218893A0 (en) 2012-05-31
EA021669B1 (ru) 2015-08-31
ES2572177T3 (es) 2016-05-30
US20160145345A1 (en) 2016-05-26
EP2397496A2 (en) 2011-12-21
KR20100101016A (ko) 2010-09-15
KR20130023356A (ko) 2013-03-07
SG196835A1 (en) 2014-02-13
BRPI0614040B1 (pt) 2020-02-04
EP2397499A3 (en) 2013-12-25
NO20080302L (no) 2008-04-15
EP2397497A2 (en) 2011-12-21

Similar Documents

Publication Publication Date Title
UA102667C2 (uk) Людське нейтралізуюче антитіло проти в7rp1
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
WO2008105886A3 (en) HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
UA92505C2 (uk) Композиції на основі антитіла проти cd3
WO2005103081A3 (en) Human monoclonal antibodies against cd20
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
UA106194C2 (uk) Діагностика та лікування раку із застосуванням антитіла до ereg
UA109633C2 (uk) Антитіло людини проти тканинного фактора
WO2005110474A3 (en) HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2008019199A3 (en) FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
GEP20125612B (en) Prlr-specific antibody and usage thereof
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
WO2006102395A3 (en) Delivery systems and methods for diagnosing and treating cardiovascular diseases
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
MA38161A1 (fr) Anticorps anti-bmp-6
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
IL185653A0 (en) Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1
WO2008118324A3 (en) Composition and method of treating cancer with an anti-uroplakin ib antibody
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
MY152169A (en) Human anti-b7rp1 neutralizing antibodies
MY185086A (en) Human anti-b7rp1 neutralizing antibodies
CY1117637T1 (el) Ανθρωπινα anti-b7rp1 εξουδετερωτικα αντισωματα
UA98100C2 (uk) Гуманізоване моноклональне антитiло, яке зв'язується з та нейтралізує людський nogo